KYNB Stock Forecast & Price Target

Kyntra Bio is attractive fundamentally because the amended NovaQuest royalty terms reduce balance-sheet overhang, preserve all subsequent EVRENZO royalties after $15 million, and leave the company with about $53 million in pro forma cash and runway into 4Q27. Its core value driver is FG-3246, the only CD46-directed ADC in mCRPC development, with encouraging Phase 1/1b signals, a smart Phase 2 design, and an expected interim futility readout in 4Q26 that could validate a differentiated, non-PSMA strategy. Roxadustat adds a second upside lever through a finalized pivotal Phase 3 protocol for LR-MDS, while the company’s broader cash discipline and simplified capital structure support execution without sacrificing near-term clinical optionality.

Kyntra Bio is vulnerable to multiple fundamental headwinds, with its pipeline failing to meet clinical efficacy endpoints for FG-3246 and FG-3180 in prostate cancer and a safety signal emerging from clinical studies, both of which undermine confidence in development success. Manufacturing issues could further impede regulatory approval or restrict commercial penetration, while regulators may impose additional requirements that delay or prevent approval altogether. Competitive pressure is also intensifying after Pluvicto’s March 2025 label expansion into post-ARPI pre-chemo mCRPC with HR 0.41 set a high efficacy bar, and DB-1311/BNT324 is already in phase 3 ahead of FG-3246, likely limiting KYNB’s market opportunity and reimbursement leverage.